Article | January 29, 2024

Leveraging Current Technology And Regulatory Frameworks To Deliver Patient Access Today

Source: Germfree
gettyimages-1273886962 therapeutics

The pharmaceutical industry is shifting towards decentralized manufacturing models in order to improve patient access to life-changing therapies. Regulatory bodies like the FDA and MHRA have provided guidelines on different manufacturing models. The FDA has defined four types of manufacturing models: centralized, distributed, decentralized, and point-of-care. The EU has also published updates on regulating decentralized manufacturing. Infrastructure is a crucial factor in improving patient access to cell and gene therapies, and there have been delays in their launch. Hospital-based therapeutics, particularly CAR-Ts, are emerging as an approach to improve patient access, but questions around reimbursement and widespread adoption remain.

Overcoming bottlenecks such as quality oversight, comparability between sites, and technology innovation is necessary to make decentralized manufacturing a reality. The existing technology and infrastructure are sufficient to deliver high-quality decentralized manufacturing. The partnership between Title21 and Germfree aims to integrate modular and mobile cleanroom facilities with adaptable software solutions to create a unified system for multiple manufacturing sites. This approach allows for standardized processes, remote monitoring, and control, and centralized quality oversight. Innovation and collaboration are needed to improve affordability and patient access to cell and gene therapies.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online